Subscribe To
Revolution medicines to report financial results for third quarter 2023 after market close on november 6, 2023
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing ...
October 31, 2023, 4:15 pm
The bitcoin white paper is now officially 15 years old
Bitcoin marked the first time money could be sent over the web without any intermediaries. A novel econ...
October 31, 2023, 1:59 pm
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev...
October 31, 2023, 9:05 am
Opthea to present at eyecelerator forum at the 2023 american academy of ophthalmology (aao) conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing ...
October 30, 2023, 5:30 am
Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t
– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to...
October 27, 2023, 1:25 pm
Top payments innovations for consumers in 2023
The manner in which we make payments is changing. Traditional payment methods, such as cash and checks, are rapidly being phased out in favor of a sle...
October 27, 2023, 12:45 pm
Monte rosa therapeutics announces $25 million registered direct offering, priced at- the-market under nasdaq rules
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing ...
October 26, 2023, 8:30 pm
Catalyst pharmaceuticals reports fda approval of agamree® (vamorolone) for duchenne muscular dystrophy granted to santhera pharmaceuticals
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American...
October 26, 2023, 7:19 pm
What is the hideaways crypto and how to buy it?
What Is The Hideaways Crypto and How to Buy It? Hideaways Crypto is a cryptocurrency project that seeks to transform the landscape of real estate inve...
October 25, 2023, 2:23 pm
Phathom pharmaceuticals to participate in upcoming investor conferences
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing ...
October 25, 2023, 8:01 am
Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023
GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n...
October 25, 2023, 7:30 am
Singular genomics to report third quarter 2023 financial results on november 14, 2023
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging ...
October 24, 2023, 4:22 pm
Highlight from kinnos recognized as one of time’s best inventions of 2023
Innovative colorization technology that makes cleaning visible is honored by TIME for its ability to improve cleaning quality in hospitals by 95%, hel...
October 24, 2023, 1:17 pm
Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-car...
October 24, 2023, 12:00 pm
Moderna and caris life sciences partner to develop mrna oncology therapeutics
Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and molecular science firm Caris Life Science...
October 24, 2023, 10:21 am
Arbutus to report third quarter 2023 financial results and provide corporate update
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...
October 24, 2023, 7:30 am
Catalyst pharmaceuticals to report third quarter 2023 financial results on november 8, 2023
The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) — Catalyst P...
October 23, 2023, 12:03 pm
One world lithium initiates bench test of lithium carbonation extraction technology
One World Lithium Inc. (CSE:OWLI, OTCQB:OWRDF) announced that per its previously announced agreement with MatterGreen (MG), MG has commenced a bench t...
October 23, 2023, 10:06 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Roche enters into a definitive agreement to acquire telavant including rights to novel tl1a directed antibody (rvt-3101) for the treatment of inflammatory bowel disease from roivant
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and ...
October 23, 2023, 5:00 am